Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diospyros lotus leaf extract (DLE) is a botanical extract derived from the leaves of the date plum or Caucasian persimmon tree. It is primarily composed of flavonoid compounds, with myricitrin being the most abundant constituent, alongside gallic acid, astragalin, and myricetin. DLE has demonstrated a range of pharmacological activities in preclinical models, including antipruritic effects mediated by the inhibition of STAT3 signaling and gastrin-releasing peptide receptors (GRPR). In metabolic research, it has shown anti-obesity and hepatoprotective properties by activating the AMPKα pathway, which in turn upregulates lipolysis and fatty acid oxidation regulators such as PPARα and CPT1. Currently, DLE is utilized as a research compound and is not associated with a specific pharmaceutical developer for commercial use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diospyros lotus leaf extract.